ICER backs survival assessment of Novartis, Kite CAR Ts

In a draft scoping document released Wednesday, the Institute for Clinical and Economic Review said an upcoming meeting on the comparative effectiveness and value of chimeric antigen receptor (CAR) T cell candidates from Novartis AG (NYSE:NVS; SIX:NOVN) and Kite Pharma Inc. (NASDAQ:KITE) should focus on survival as the primary outcome measure.

ICER's California Technology Assessment Forum (CTAF) will hold a public meeting on March 2, 2018, to compare Novartis’ tisagenlecleucel-T (CTL019) and Kite’s axicabtagene ciloleucel (KTE-C19) to National Comprehensive Cancer Network (NCCN)-recommended, approved treatments. Both products are under FDA review for relapsed or refractory B cell cancers...